Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s genomic ambitions

This article was originally published in The Gray Sheet

Executive Summary

Trending of IVD field toward health information could result in "a shuffling of the whole market," approaching a $60 bil.-$80 bil. cap, compared with "$24 bil. for the in vitro market today," Diagnostics Division head Heino von Prondzynski says in annual media conference Feb. 4. "The demarcation lines are going to change. The in vivo...imaging techniques are going to move close together" within the next 10 years, he predicts. "This is the direction in which we as Roche are going to have to go - as a diagnostics company or as a health information company"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel